Statins and chronic heart failure: do we need a large-scale outcome trial?  by Krum, Henry & McMurray, John J
REVIEW ARTICLE
Statins and Chronic Heart Failure:
Do We Need a Large-Scale Outcome Trial?
Henry Krum, MBBS, PHD, FRACP,* John J. McMurray, MB, MD, FRCP, FACC, FESC†
Melbourne, Australia, and Glasgow, United Kingdom
Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) are of proven clinical
benefit in coronary heart disease, at least in those patients who do not have overt chronic heart
failure (CHF). However, as there have been no prospective clinical trials of statins in CHF
patients, the question arises as to whether the benefits observed in the absence of CHF can
be necessarily inferred in those patients in whom CHF is established. In this review, the
evidence base stating support of the use of statins in CHF is presented, as well as theoretical
considerations as to why these agents may not necessarily be of benefit in this setting. The
beneficial potential of statins clearly relates to their plaque stabilization properties and
associated improvements in endothelial function, which together should reduce the risk of
further infarction and, perhaps, the ischemic burden on the failing ventricle. Furthermore,
these agents may have beneficial effects independent of lipid lowering. These include actions
on neoangiogenesis, downregulation of AT1 receptors, inhibition of proinflammatory
cytokine activity and favorable modulation of the autonomic nervous system. The potential
adverse effects of statins in CHF include reduction in levels of coenzyme Q10 (which may
further exacerbate oxidative stress in CHF) and loss of the protection that lipoproteins may
provide through binding and detoxifying endotoxins entering the circulation via the gut. In
support of these possibilities are epidemiologic data linking a lower serum cholesterol with a
poorer prognosis in CHF. These uncertainties indicate the need for a definitive outcome trial
to assess the efficacy and safety of statins in CHF, despite their current widespread,
nonevidence based use in this population. (J Am Coll Cardiol 2002;39:1567–73) © 2002 by
the American College of Cardiology Foundation
The discussion of the treatment of chronic heart failure
(CHF) usually focuses on the treatment of the heart failure
syndrome per se, often forgetting the underlying causes
of CHF. In western society, this is most commonly
coronary heart disease (CHD), and there is clearly a
complex interplay between the effects of treatment for
CHF and those for CHD. One important area where this
interplay has yet to be fully worked out concerns the use
of hydroxymethylglutaryl-coenzyme A (HMG-CoA) re-
ductase inhibitors or “statins.” In this article, we review
the evidence for and against the use of these agents in
patients with CHF and suggest that there is sufficient
uncertainty about the effects of statins to merit a defin-
itive morbidity/mortality clinical trial.
CHD AS THE UNDERLYING CAUSE OF CHF
Statins are of proven clinical benefit in patients with CHD,
at least in those who do not have CHF (1–3). Consequently,
the greatest potential benefit of statins in CHF is probably
in those patients with CHD. Importantly, these patients
make up the bulk of those randomized in existing trials
(4–10) (Table 1). Indeed, it is highly likely that the
proportion assumed to have CHD is actually an underesti-
mate, as patients with CHF thought not to have CHD are
often found to have coronary artery disease if invasive
investigation is undertaken (11).
IMPORTANCE OF ACUTE CORONARY
EVENTS AS A CAUSE OF PROGRESSION OF CHF
Fundamental to the proposition that statins may reduce the
progression of CHF is the belief that acute coronary events
(which statins reduce) contribute to this progression. There
is good evidence that this is, indeed, the case.
In the Studies Of Left Ventricular Dysfunction
(SOLVD), interim myocardial infarction (MI) and unstable
angina increased the risk of death and of hospitalization for
CHF (12) (Fig. 1). Myocardial infarction had a particularly
powerful effect, more than doubling the one-year risk of
CHF hospitalization from 8.6% to 20.5% (relative risk: 2.1,
95% confidence interval: 1.6 to 2.6).
A similar insight can be gained from the Scandanavian
Simvastatin Survival Study (4S) (1). In the placebo group of
4S, 52% of patients developing CHF had a preceding,
postrandomization, MI (i.e., in many, if not most,
patients a recurrent infarction) (13). Of those not devel-
oping CHF, the proportion having an interim infarction
was only 16%.
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DO STATINS REDUCE ACUTE
CORONARY EVENTS IN PATIENTS WITH CHF?
There are two facets to this question. First, do acute
coronary events occur at a sufficiently high frequency to be
impacted upon, and, second, do statins retain their anti-
coronary efficacy in patients with CHF? Here the assump-
tion is made that acute coronary events have the same
pathogenesis in patients with CHF as in other CHD
patients.
The first question is more difficult to answer. Recognized
MIs are uncommon in CHF trials (4). This may be because
infarction is more commonly fatal in patients with CHF,
and death is then classified as sudden death rather than due
to MI (14). There is some post-mortem evidence to support
this view (15). Similarly, infarction causing worsening CHF
may be misclassified by end point committees (16). It is also
possible, however, that coronary disease becomes “burnt
out” as CHF worsens. Thus, new coronary events are
uncommon, and progression of disease occurs in other ways.
In this context, it is important to note that the SOLVD data
on coronary events and CHF progression is derived from
pooling of both the prevention and treatment trials (12).
Review of data from CHF trials and registers also suggests
that angina may be more common in milder CHF and less
so in patients with more advanced CHF. Overall, therefore,
it is likely that acute coronary events are probably a more
important mechanism of progression in patients with lesser
degrees of CHF and left ventricular (LV) systolic dysfunc-
tion.
In such patients, there is evidence that statins retain their
efficacy in preventing acute ischemic events. Of the three
large statin secondary prevention studies (1–3), only the
Cholesterol And Reduction of Events (CARE) (2) study
documented left ventricular ejection fraction (LVEF). Al-
though patients with CHF and patients with an LVEF
0.25 could not be randomized, 706 patients with an
LVEF of 0.40 (and 0.25) were randomized. Pravastatin
was equally effective in reducing coronary events in these
patients as in patients with an LVEF of 0.40 (Fig. 2).
ADDITIONAL ANTI-ISCHEMIC
BENEFITS OF STATINS IN CHF
While the primary actions of statins are undoubtedly on
coronary syndromes (i.e., MI and unstable angina), revers-
ible myocardial ischemia and myocardial hibernation may be
other ischemic mechanisms through which statins might
improve left ventricular function (17) and CHF clinical
status. Statins can reduce “silent” reversible myocardial
ischemia, though the frequency of occurrence of this is
unknown in CHF and its potential pathophysiological
importance speculative (18). Conversely, myocardial hiber-
nation appears to be common in CHF, and there is growing
evidence that its reversal can improve left ventricular func-
tion (19). Whether or not statins, by improving coronary
endothelial function and increasing blood flow, can bring
this reversal about is, of course, unknown.
Abbreviations and Acronyms
CARE  Cholesterol And Recurrent Events trial
CHD  coronary heart disease
CHF  chronic heart failure
ELITE  Evaluation of Losartan In The Elderly
trial
HDL  high-density lipoprotein
HMG-CoA  hydroxymethylglutaryl-coenzyme A
HPS  Heart Protection Study
LDL  low-density lipoprotein
LV  left ventricular
LVEF  left ventricular ejection fraction
MI  myocardial infarction
SOLVD  Studies Of Left Ventricular Dysfunction
4S  Scandanavian Simvastatin Survival Study















Ischemic etiology (%) 65 67 79 57 — 56 69
Previous MI (%) 48 — 58 — 55 51 64
Angina (%) — — — — 53 — —
CHARM  Candesartan in Heart failure–Assessment of Reduction in Mortality and morbidity; CHF  chronic heart failure; COPERNICIUS  Carvedilol Prospective
Cumulative Survival trial; ELITE II  Evaluation of Losartan in the Elderly trial II; ENABLE  Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart
Failure; MERIT-HF  Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; MI  myocardial infarction; OVERTURE  Omapatrilat Versus
Enalapril Randomized Trial of Utility in Reducing Events; Val-HeFT  Valsartan Heart Failure Trial.
Figure 1. Effect of myocardial infarction and unstable angina on risk of
death and of hospitalization for chronic heart failure (CHF) in the Studies
Of Left Ventricular Dysfunction (5). RR  relative risk.
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ADDITIONAL POTENTIAL EFFECTS OF
STATINS (INDEPENDENT OF ANTI-ISCHEMIC
EFFECTS) THAT MAY BE OF BENEFIT IN CHF
In addition to effects of statins that may directly impact on
coronary ischemia, namely restoration of endothelial func-
tion (20) and stabilization of plaque (21), a number of
additional properties of statins may be of direct relevance in
retardation of the progression of CHF. These include the
following:
1) Effects on myocardial cellular function. Lipoprotein is a
prominent component of cardiac membrane regulating
cell function. A high membrane cholesterol component
affects the enzymes required for energy production and
movement of calcium through specific channels, thus
potentially adversely influencing cardiac contractility
(22).
2) Neoangiogenesis. statins have been demonstrated to in-
duce new blood vessel growth in ischemic limbs in a
manner similar to vascular endothelial growth factor
(23). This may arise, at least in part, due to the ability of
statins to mobilize endogenous angioblastic stem cells
from bone marrow.
3) Downregulation of AT1 receptor. atorvastatin has been
shown to downregulate AT1 receptors in vascular
smooth muscle cells (24). The AT1 receptor plays a key
role in the progression of CHF as evidenced by the
therapeutic success of blockade of the renin-angiotensin-
aldosterone system in this disease.
4) Restoration of autonomic function. Congestive heart fail-
ure is associated with sympathetic activation and para-
sympathetic withdrawal (25). As this autonomic dys-
function is associated with an increase in sudden death,
restoration of autonomic function may favorably influ-
ence this outcome. Parasympathetic activity is increased
in the setting of a low saturated fat diet (26). Uncon-
trolled studies with statins have also been demonstrated
to improve autonomic function in patients with coronary
disease (27). Recently, high-dose statins have been
shown to reduce sympathetic nerve activity in rabbits
with pacing-induced heart failure (28).
5) Inhibition of proinflammatory cytokines. Congestive heart
failure is associated with activation of a number of
proinflammatory cytokines. These cytokines appear to be
integral to CHF disease progression. For example, tu-
mor necrosis factor-alpha gene expression is increased
within the myocardium of the failing heart and is
associated with necrosis, apoptosis and pathologic fibro-
sis (29). Statins have been found to reduce levels of
tumor necrosis factor-alpha and other proinflammatory
cytokines thought important to CHF disease progres-
sion (e.g., interleukin-6) in plasma (30) and ex vivo
mononuclear cell culture of normal subjects (31).
All of the above may be important mechanisms, indepen-
dent of effects on ischemia and, indeed, lipid-lowering, that
may underlie the potential benefit of statins in the treatment
of CHF.
ARE THERE ANY EXISTING PRECLINICAL
DATA THAT STATINS ARE OF BENEFIT IN CHF?
Statin therapy has been shown to improve ventricular
function in various experimental animal models of CHF,
particularly those where heart failure is induced by coronary
artery ligation with consequent MI and subsequent patho-
logic ventricular remodelling.
In a murine model of CHF after MI, fluvastatin de-
creased mortality in these mice (32) with reductions in LV
cavity dilation, myocyte hypertrophy and interstitial fibrosis.
Heart failure, as assessed by pleural effusion and lung/body
weight ratio, was reduced.
Similar findings were also observed with cerivastatin in a
rat model of CHF after MI (33). Left ventricular dimen-
sions and end-diastolic pressures were restored towards
sham values in cerivasatin-treated animals compared with
placebo. This was associated with a reduction in deposition
of pathologic collagen.
It is important to note that, although the above studies
utilized models of CHF induced by an initial episode of
ischemia and infarction (specifically, coronary artery liga-
tion), ongoing pathologic ventricular remodeling is not due
to further ischemic events. Therefore, the beneficial impact
of statins in this setting is unrelated to their impact on
subsequent ischemia and supports noncoronary actions of
these drugs on the myocardium.
In vivo and in vitro studies also support the use of statins
in animal and cell culture models of cardiac hypertrophy
(34 –36). Statin therapy reduces cardiac hypertrophy in
these settings and appeared to do so, at least in part, via
inhibition of the renin-angiotensin-aldosterone system
(34,35).
Figure 2. Effect of pravastatin on coronary events in patients with coronary
artery disease and a left ventricular ejection fraction (LVEF) of 0.40
enrolled in the Cholesterol And Recurrent Events trial (2). CHD 
coronary heart disease. White bar  placebo; shaded bar  pravastatin.
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ARE THERE ANY EXISTING CLINICAL
DATA THAT STATINS ARE OF BENEFIT IN CHF?
Prevention of new heart failure. Lowering cholesterol
with statins results in a significant reduction in mortality
and cardiovascular end points in comparison with placebo in
patients with relatively preserved ventricular function and
both normal and higher levels of plasma cholesterol and
proven coronary artery disease (1–3).
The 4S study has demonstrated, albeit in a post-hoc
analysis, a significant reduction in development of subse-
quent heart failure in patients with preserved ventricular
function at the time of entry into the study (13).
Retardation of progression of established heart failure. No
large-scale clinical trial to date with statins in patients with
CHD has prospectively enrolled patients with CHF (these
patients have, in fact, been actively excluded), and no
prospective trial of statins has been specifically conducted in
patients with CHF.
Retrospective, nonrandomized, subset analyses do, how-
ever, suggest a possible benefit of statins in patients with
CHF.
In the 4S study, the mortality rate in patients developing
CHF was 25.5% in the simvastatin group compared with
31.9% in the placebo group (13) (Fig. 3).
In the Evaluation of Losastan In The Elderly trial II
(ELITE) II study, 11% of patients were receiving statins at
enrollment, and this proportion increased to 19.6% during
the study. Although nonrandomized, there was a signifi-
cantly lower mortality in patients receiving statins (10.6%)
compared with those who were not (17.6%) (37).
Furthermore, in a small study of post-MI patients (38),
those with an LVEF 40% (n  8) had a 6 absolute %
improvement in LVEF versus baseline after 12 weeks
simvastatin therapy.
The Heart Protection Study (HPS), a recently reported
trial of patients with or at high risk of vascular disease and
a total plasma cholesterol level3.5 mmol/l did not entirely
exclude heart failure patients on entry (39). Therefore,
prospective analysis of the impact of statins on this subgroup
may be forthcoming in the future. There were slightly fewer
deaths from heart failure in the simvastatin group compared
with placebo, but this did not approach significance. De-
tailed information of the impact of statins on heart failure
awaits further analysis (as stated earlier) as well as full
publication of the HPS results.
DO PATIENTS WITH CHF HAVE
SERUM CHOLESTEROL CONCENTRATIONS
HIGH ENOUGH TO MERIT STATIN TREATMENT?
Whether statins have a worthwhile benefit in patients with
relatively low serum low-density lipoprotein (LDL) concen-
trations (e.g.,3.2 mmol/l) is a controversial question. It is,
however, one that is particularly relevant in CHF where
patients often have lower serum cholesterol concentrations
than patients with CHD and no CHF. A direct relationship
has been demonstrated between plasma cholesterol level and
prognosis (40). If one accepts the view that the most benefit
of statins is seen in patients with a high starting LDL or
total cholesterol and/or in those experiencing the greatest
fall, there may not be as much to gain with this type of
treatment in CHF, particularly if advanced. Alternatively, if
a substantial proportion of the benefit of statins in CHF is
conferred via the non–lipid-lowering (pleiotropic) proper-
ties of these agents, then baseline plasma cholesterol levels
may not be critical.
ARE THERE POTENTIAL
DRAWBACKS TO STATIN THERAPY IN CHF?
So far, it has been argued that the cholesterol-lowering and
other actions of statins are potentially beneficial in CHF.
Are there, however, any potential drawbacks of statin
therapy in CHF?
Serum cholesterol concentration and outcome in
CHF. At least two observational studies have suggested
that a low serum cholesterol concentration is predictive of a
worse prognosis in CHF (41,42). This effect persists after
adjustment for other potentially important differences that
might influence prognosis. However, among 132 patients
listed for cardiac transplantation, low high-density lipopro-
tein (HDL) (33 mg/dl) was the most powerful predictor
of survival (69%) versus 83% if HDL 33 mg/dl (43).
The “ubiquinone hypothesis.” Ubiquinone (also known as
coenzyme Q10) is a ubiquitous, lipid-soluble, micronutrient
that acts as a coenzyme in mitochrondrial oxidative phos-
phorylation. Its best known function is as a potential
antioxidant. Uniquinone can also be synthesized endog-
enously via the mevalonate-isoprene pathway (Fig. 4) as a
result of the action of HMG-CoA reductase. Not surpris-
ingly, therefore, plasma and, possibly, tissue ubiquinone
concentrations are reduced during treatment with a statin,
both as a consequence of a reduction in ubiquinone-rich
LDL cholesterol and inhibition of its synthesis (44). The
physiologic consequences of this interaction are unknown.
However, CHF is known to be a state of pro-oxidant stress
Figure 3. Effect of simvastatin on mortality among patients developing
chronic heart failure (CHF) compared with those without clinical evidence
of CHF in the Scandinavian Simvastatin Survival Study trial (1). White
bar  placebo; shaded bar  simvastatin.
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(45), and antioxidant properties of drug therapies have been
postulated to contribute to their clinical benefit. In addition,
some (but not all) reasonably well-designed clinical trials
have shown that dietary ubiquinone supplementation can
improve exercise tolerance in patients with CHF (46–51),
raising concerns that ubiquinone depletion (via statin ther-
apy) might have adverse clinical effects. Against these
theoretical concerns, however, is the recent observation that
statins may have antioxidant effects via reduction of vascular
reduced nicotinamide adenine dinucleotide phosphate oxi-
dase expression (52).
The “endotoxin hypothesis.” Lipoprotein in plasma can
bind and detoxify endotoxins such as lipopolysaccaride
entering the circulation via the gut. In the setting of CHF,
endotoxin may be an important mediator of CHF disease
progression via activation of proinflammatory cytokines
such as tumor necrosis factor-alpha. It is, therefore, argued
that lipid-lowering with statin therapy may enhance endo-
toxemia by reducing plasma levels of lipoproteins (53). This
may, in turn, result in further elevation of plasma levels of
proinflammatory cytokines, levels of which are strongly
linked to adverse prognosis in CHF (54). In support of this
hypothesis, plasma levels of lipopolysaccaride have been
shown to be elevated in patients with CHF (55), although
the impact of statin therapy on this parameter has not been
examined in this setting.
WHY WE NEED A DEFINITIVE
TRIAL OF STATINS IN HEART FAILURE
The preceding review summarizes arguments for and
against the use of statins in patients with established CHF.
The most powerful argument for a definitive trial is that
these agents are becoming widely used in the management
of the patient with CHF, presumably mostly in those with
an ischemic etiology for their disease. Only very few recent
trials of systolic CHF have, however, reported baseline rates
of use of lipid-lowering therapy (4,6,8,10,56) (Table 2).
This is in the absence of any prospective randomized trial
data addressing mortality, morbidity and/or effects on hos-
pitalization and despite the possibility that statins could be
harmful in CHF.
If it is accepted that there is a need for definitive (as
opposed to surrogate) data on statins in CHF, many
questions remain about the design of such a trial. These
include the etiology of CHF (ischemic vs. nonischemic
etiology), the severity of the disease (e.g., can patients be too
sick to benefit) and the cutoff level for total and/or LDL
cholesterol. These issues involve both ethical considerations
as well as addressing the question of whether the putative
benefits of statin therapy occur via a reduction in elevated
lipid levels, anti-ischemic effects or mechanisms indepen-
dent of the above. The major ethical consideration is clearly
Figure 4. The mevalonate-isoprene pathway.
Table 2. Percentage Use of Lipid-Lowering Therapies in Recently Reported (MERIT-HF,











Active drug Metoprolol CR/XL Bucindolol Losartan/Captopril Candesartan Bosentan
NYHA class studied II–IV III–IV II–IV II–IV IIIB–IV
% Lipid-lowering use 26 23* 11* 41 45
*Statin use only.
BEST  Bucindolol Evaluation of Survival Trial; NYHA  New York Heart Association. Other abbreviations as in Table 1.
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whether the overwhelming benefits of statin therapy in
patients with vascular disease, but without ventricular dys-
function, are necessarily able to be transferred to patients
with established heart failure. The preceding review would
argue strongly that this is not clearly the case.
Summary. Despite major issues in study design, as previ-
ously described, there appears to be a clear need for a
definitive prospective trial of statin therapy in patients with
CHF. Such a trial is of great importance given the wide-
spread use of these agents, the uncertainty of the outcome
(given both beneficial and adverse mechanistic data) and the
absence of definitive prospective studies in this specific
patient population.
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